COMPOSITIONS COMPRISING BACTERIAL STRAINS
Provided are compositions comprising a bacterial strain of the genus Blautia , for use in a method of increasing the microbiota diversity and/or stability of the microbiota of a subject.
1 .- 40 . (canceled)
41 . A method of inducing a temporal variation in the microbiota of a subject having a stroke in need thereof, comprising administering to the subject a composition that comprises a therapeutically effective amount of a bacteria strain of the genus Blautia with at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:5, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62, wherein the administering is effective to induce the temporal variation in the microbiota of the subject having the stroke.
42 . The method of claim 41 , wherein the subject has the stroke and the administering induces a temporal increase of a bacteria of the species Mucispirillum schaedleri , from the family Lachnospiraceae, from the family Ruminococcaceae, from the genus Clostridium XIVa, or of the species Oscillibacter valericigenes , or a temporal decrease of the species Barnesiella intestinihominis , of the species Ruminococcus flavefaciens , of the species Alistipes finegoldii , of the species Staphylococcus lentus , from the genus Staphylococcus , from the genus Prevotella , from the genus Barnesiella , from the family Lachnospiraceae, or of the species Lactobacillus johnsonii .
43 . The method of claim 41 , wherein the bacteria strain is dried.
44 . The method of claim 41 , wherein the pharmaceutical composition comprises de minimis amounts of other bacterial strains.
45 . The method of claim 41 , wherein the therapeutically effective amount of the bacteria strain comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU)/g of the bacteria strain with respect to the total weight of the pharmaceutical composition.
46 . The method of claim 41 , wherein the therapeutically effective amount of the bacteria strain comprises at least 1×10 6 CFU/g of the bacteria strain with respect to the total weight of the pharmaceutical composition.
47 . The method of claim 41 , wherein the bacteria strain comprises a polynucleotide sequence of a 16S rRNA gene that has at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO:5, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62.
48 . The method of claim 41 , wherein the bacteria strain comprises the polynucleotide sequence of SEQ ID NO:5.
49 . The method of claim 41 , wherein the bacteria strain is of the species Blautia hydrogenotrophica.
50 . The method of claim 41 , wherein the bacteria strain is the strain deposited under accession number DSM 10507 or the strain deposited under accession number DSM 14294.
51 . The method of claim 41 , wherein said administering comprises oral, rectal, nasal, buccal, sublingual, or subcutaneous administration.
52 . The method of claim 41 , wherein the pharmaceutical composition is formulated for delivery to an intestine of the subject.
53 . The method of claim 41 , wherein the pharmaceutical composition is encapsulated.
54 . The method of claim 41 , wherein the pharmaceutical composition comprises an enteric coating.
55 . The method of claim 41 , further comprising administering an additional therapeutic agent to the subject.
56 . The method of claim 41 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, diluent, or carrier.
57 . The method of claim 41 , wherein the subject is a human.